Are WHO’s Revised Norms Masking Safety Signals In Vaccines?
Public health experts have raised concerns over the WHO’s revised classification approach for adverse events following immunization (AEFI), claiming that it could well make post-marketing surveillance redundant, missing important safety signals in vaccines.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.